News >

Predictive Assays Help Personalize Care in Early-Stage HR+ Breast Cancer

Caroline Seymour
Published: Wednesday, Jan 15, 2020

Stephanie L. Graff, MD

Stephanie L. Graff, MD

The 21-gene recurrence score assay demonstrated predictive value in identifying whether patients with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer will require chemotherapy in addition to endocrine therapy, according to the results of the phase III TAILORx trial, said Stephanie L. Graff, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication